Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION Study of dordaviprone after radiotherapy for H3 K27M-mutant diffuse glioma
NL-OMON59522Phase 3Recruiting
- Sponsor
- Chimerix Inc.
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse midline glioma (DMG) comparing Dordaviprone with Placebo (2 arms). Primary endpoint: Overall survival. Started Jun 2023; status: recruiting.
02
Drugs
dordaviprone
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NL-OMON59522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59522.